Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for GVHD Prevention in RIC HSCT
NCT01754389Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2013
- Primary completion
- May 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Started Jan 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01754389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754389.